GSK: Blenrep’s Return Is Just The Start Of Our Oncology Renaissance

GSK’s Blenrep’s initial regulatory approval as a treatment for second-line relapsed/refractory multiple myeloma, marks just the first big step in what could be a remarkable comeback for the antibody-drug conjugate.

Blenrep (belantamab mafodotin), which became the first BCMA-targeting drug to reach the market in 2020 following accelerated approval, was withdrawn...